PD-1, PD-L1, and PD-L2 Immunoexpression in Mycosis Fungoides Biopsies

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Mycosis fungoides (MF) is a slow-progressing cutaneous T-cell lymphoma with a worse prognosis in advanced stages.
• Understanding immune markers like programmed death-1 (PD-1) and its ligands (PD-L1, PD-L2) is crucial for advanced MF management.

Purpose of the Study:

• To investigate the immunoexpression of PD-1, PD-L1, and PD-L2 in mycosis fungoides patient biopsies.
• To compare expression levels between early and later disease phases, and across CD4/CD8 positivity, age, and sex.

Main Methods:

• Analysis of 82 MF patient biopsies using immunohistochemical staining for PD-1, PD-L1, and PD-L2.
• Quantification of positivity scores in tumor cells and the tumor microenvironment.
• Statistical comparison of immune scores based on lesion phase and patient demographics.

Main Results:

• Higher PD-1, PD-L1, and PD-L2 expression levels were observed in later-phase MF lesions compared to early-phase lesions.
• Expression levels were not significantly affected by CD4/CD8 positivity, age, or sex.
• Effect sizes for PD-1, PD-L1, and PD-L2 differences between phases were small to moderate.

Conclusions:

• Elevated PD-1 pathway expression in advanced MF suggests potential therapeutic targets.
• Immune checkpoint inhibitors may offer a treatment strategy for advanced-stage mycosis fungoides.
• Further research with larger cohorts and clinical staging correlation is warranted.